SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US

SpringWorks Therapeutics

28/11/2023 13:54

Nov 28 (Reuters) - SpringWorks Therapeutics'  SWTX.O 
drug for treating adult patients with a type of rare
non-cancerous soft-tissue tumor will be sold in the U.S. at a
list price of $29,000 for a 30-day supply, the company said on a
conference call on Tuesday.
    The U.S. health regulator on Monday approved the monotherapy
branded as Ogsiveo, making it the first approved treatment for
desmoid tumors, which are abnormal growths that occur in
connective tissues and are associated with a high rate of
recurrence.
    
    

 (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi
Majumdar)
 ((Pratik.Jain@thomsonreuters.com;))